A 73-year-old Caucasian female patient presented for three annular erythematous lesions on the left leg and buttock, persisting for two months, clinically interpreted as erythema annulare centrifugum. Routine laboratory findings were within the normal ranges, Borrelia serology and wet mount microscopy for mycosis were negative. Histologic examination confirmed the diagnosis of superficial erythema annulare centrifugum. Since no association of erythema annulare centrifugum with concomitant bacterial or viral infections, or active systemic disease was found in our patient, we considered the possible activation of her previous breast cancer operated on in October 2000.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Erythema annulare centrifugum in a case of indolent lymphoma: a case report.
Int J Dermatol
January 2025
Division of Dermatology, Department of Medicine, National University Hospital, Singapore.
Resolution of Erythema Annulare Centrifugum With Lung Cancer Drug Therapy: A Case Report.
Cureus
November 2024
Department of Dermatology, Japanese Red Cross Akita Hospital, Akita, JPN.
Tumor-associated erythema annulare centrifugum is commonly observed in leukemia and lymphoma. In this case, we reported erythema annulare centrifugum associated with lung cancer that resolved following targeted drug therapy. A 71-year-old man with psoriasis visited our hospital with erythema annulare and pruritus.
View Article and Find Full Text PDFClinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1/PD-L1 inhibitors.
Arch Dermatol Res
October 2024
College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
PD-1/PD-L1 inhibitors have increasingly been associated with the occurrence of subacute cutaneous lupus erythematosus (SCLE), but the clinical characteristics and outcomes remain under-explored. Literature on PD-1/PD-L1 inhibitors induced SCLE was retrieved from Chinese and English databases until June 31, 2024, and clinical data of patients were extracted for retrospective analysis. Twenty-nine patients participated, with a median age of 63 years (range 43, 80).
View Article and Find Full Text PDFErythroderma Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Atopic Dermatitis: A Case Report.
Cureus
September 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Article Synopsis
- Cutaneous reactions to mRNA COVID-19 vaccines can include various skin issues, especially in patients with existing dermatologic diseases.
- A case report details a 73-year-old man with atopic dermatitis who developed severe erythroderma after each Pfizer-BioNTech vaccine dose, which covered 95% of his body.
- Quick identification and treatment of erythroderma are crucial to prevent serious complications, highlighting the need for awareness of this reaction in susceptible individuals.
Erythema nodosum as first clinical sign of acute Borrelia burgdorferi infection.
Braz J Infect Dis
December 2024
Onkoderma- Clinic for Dermatology, Venereology and Dermatologic Surgery, Bulgaria; Department of Dermatology and Venereology, Medical Institute of Ministry of Interior, Bulgaria.
Article Synopsis
- Lyme borreliosis, commonly known as Lyme disease, is a worldwide tick-borne infection caused by the Borrelia burgdorferi species, often starting with a distinctive erythema migrans rash at the bite site.
- Other skin symptoms may also appear initially, leading to potential misdiagnosis and treatment delays, highlighting the need for comprehensive evaluation of clinical findings, serology, and histology.
- A case of a 78-year-old woman revealed erythema nodosum as her initial manifestation following a tick bite; she was effectively treated with antibiotics and anti-inflammatory medications, and prescribed adjustments for her outpatient care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!